- Human（1）
- Mouse（1）
No data
- -（1）
- His Tag（1）
No data
- HEK293（2）
No data
- Biotin-labeled（1）
- Unconjugated（1）
No data
- RUO（2）
No data
- No（2）
No data
- 100ug/$340.00
- 1mg (500ug X 2)/$2140.00
No data
- 25ug/$360.00
- 200ug/$1420.00
No data
| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| IGFBP-2 | Human IGFBP-2 Protein, His Tag (MALS verified) |  Human | HEK293 |  | MALSSDS-PAGE | $340.00 100ug | ||
| IGFBP-2 | Avitag IG2-M82D3 | Biotinylated Mouse IGFBP-2 Protein, His,Avitag™&Flag Tag (MALS verified) |  Mouse | HEK293 |  | MALSSDS-PAGE | $360.00 25ug |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Cenicriviroc mesylate | CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 | Phase 3 Clinical | Tobira Therapeutics Inc, Takeda Pharmaceutical Co Ltd | Prediabetic State; HIV Infections; Acquired Immunodeficiency Syndrome; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis; Coronavirus Disease 2019 (COVID-19); AIDS Dementia Complex; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders | 상세 |
| SB-728-T | SB-728mR-T; SB-728-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | 상세 |
| Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | HIV Infections; Acquired Immunodeficiency Syndrome; Colorectal Neoplasms | 상세 |
| Leronlimab | HuPRO-140; PA-14; PRO-140 | Phase 2 Clinical | Cytodyn Inc | HIV Infections; Solid tumours; Metabolic Dysfunction-Associated Steatotic Liver Disease; Rectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Triple Negative Breast Neoplasms; Colorectal Neoplasms | 상세 |
| BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Pancreatic Neoplasms; Diabetic Nephropathies; Hyperplasia; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | 상세 |
| Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Metabolic Dysfunction-Associated Steatotic Liver Disease | 상세 |
| AGT 103-T | AGT 103-T | Phase 1 Clinical | American Gene Technologies International Inc | HIV Infections | 상세 |
| Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | HIV Infections | 상세 | |
| BMS-687681 | BMS-687681 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | 상세 |
| SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections; HIV Seropositivity | 상세 |
| LF-0376 | LF-0376 | Phase 1 Clinical | Wuxi Hillhouse biomedicine Technology Co Ltd | Solid tumours; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colorectal Neoplasms; Lymphoma | 상세 |
| OB-002 | OB-002; OB-002M; OB-002O; OB-002H; OB-002C; 5P12-RANTES; 5P12-RANTES-E66S | Phase 1 Clinical | Mintaka Medical Research Foundation | HIV Infections; Stomach Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis | 상세 |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | United States | HIV Infections | Viiv Healthcare Co | 2007-08-06 | HIV Infections; Acquired Immunodeficiency Syndrome; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hypertriglyceridemia; Arthritis, Rheumatoid; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Stroke; AIDS Dementia Complex; Cardiovascular Diseases; Inflammation; HIV Seropositivity; Sarcoma, Kaposi | 상세 |
